Stock Events

Stock Events

KalVista Pharmaceuticals 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4XC.STU. It's not an investment recommendation.
Amazon
6
AMZN
NVIDIA
5
NVDA
Alphabet
5
GOOGL
Apple
4
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetically defined diseases, competing in the same rare disease space as KalVista.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals engages in creating small molecule drugs for serious diseases, directly competing with KalVista's approach in drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is involved in developing and commercializing medicines for serious diseases, including therapies that could compete with KalVista's portfolio.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on discovering, developing, and delivering therapies for neurological diseases, competing for similar patient populations as KalVista.
AMGEN
AMGN
Mkt Cap196.12B
Amgen develops therapeutics in areas including cardiovascular disease, competing with KalVista's efforts in hereditary angioedema.
Novartis
NVS
Mkt Cap293.94B
Novartis offers a broad range of healthcare products including innovative medicines, directly competing across multiple areas including treatments for diseases targeted by KalVista.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences focuses on antiviral drugs for infectious diseases, but its expansion into other therapeutic areas could position it as a competitor to KalVista.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie works on a broad portfolio of drugs, including efforts in immunology and oncology, areas that could intersect with KalVista's therapeutic targets.

About

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
Show more...
CEO
Mr. Benjamin L. Palleiko
Employees
275
Country
Germany
ISIN
US1413841073

Listings

STU
DE
4XC.STU
XNAS
US
KALV
BOATS
BOATS
KALV.BOATS

0 Comments

Share your thoughts

FAQ

What is KalVista Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange KalVista Pharmaceuticals stocks are traded under the ticker 4XC.STU.
How many employees does KalVista Pharmaceuticals have?▼
As of July 16, 2026, the company has 275 employees.
In which sector is KalVista Pharmaceuticals located?▼
KalVista Pharmaceuticals operates in the Health & Wellness sector.
When did KalVista Pharmaceuticals complete a stock split?▼
KalVista Pharmaceuticals has not had any recent stock splits.
Where is KalVista Pharmaceuticals headquartered?▼
KalVista Pharmaceuticals is headquartered in Framingham, Germany.